Important advances have been made in gout therapeutics in 2010. In addition to the development of novel biologic agents, progress has been made in the safe prescribing of colchicine. However, colchicine also became the subject of considerable controversy in the USA when one brand of this drug was granted exclusivity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ahern, M. J. et al. Does colchicine work? The results of the first controlled study in acute gout. Aust. N. Z. J. Med. 17, 301–304 (1987).
Terkeltaub, R. A. et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 62, 1060–1068 (2010).
Zhang, W. et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312–1324 (2006).
Kesselheim, A. S. & Solomon, D. H. Incentives for drug development—the curious case of colchicine. N. Engl. J. Med. 362, 2045–2047 (2010).
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).
So, A. et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis. Arthritis Rheum. 62, 3064–3076 (2010).
US Food and Drug Administration. FDA approves new drug for gout [online], (2010).
Sundy, J. S. et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 56, 1021–1028 (2007).
Hershfield, M. S. et al. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc. Natl Acad. Sci. USA 107, 14351–14356 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
N. Dalbeth has acted as a consultant for Abbott Laboratories, Novartis, Roche and Takeda, has received speakers' honoraria from Abbott Laboratories, has received grant/research support from Centecor and Fonterra, and is a patent holder/applicant with Fonterra.
Rights and permissions
About this article
Cite this article
Dalbeth, N. Progress and controversies in treatment. Nat Rev Rheumatol 7, 77–78 (2011). https://doi.org/10.1038/nrrheum.2010.222
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.222
This article is cited by
-
Potential of vitamin C in the prevention and treatment of gout
Nature Reviews Rheumatology (2011)
